Pronova BioPharma has evolved from a long history of development and strategic growth, the key aspects of which are as follows:
-
1935: A fish oil processing factory established in 1935 by Jahres Fabrikker in Sandefjord, Norway and Johan C. Martens & Company
in Bergen
-
1986 to 1988: Norsk Hydro acquired the Johan C. Martens & Company and the Jahres Fabrikker company, to develop their omega-3 fish oil containing
EPA and DHA
-
1988: Norsk Hydro filed for patent protection in the United Kingdom for product composition and therapeutic use of active pharmaceutical
ingredient
-
1992: The patent was issued and has coverage in 26 countries. A merger between Johan C. Martens & Company and Jahres Fabrikker,
to form Pronova Biocare
-
1994: Registration of the first commercialised product for the HTG indication in Europe was granted with the commercial launch
in Italy
-
1999: Registration of the active pharmaceutical ingredient for the Post-MI indication in Europe was granted
-
2004 to 2005: Ferd Private Equity Fund I (now Herkules I) acquired Pronova Biocare. Consumer and industrial brands sold, to cultivate Pronova
Biocare as a pharmaceutical company
-
2004: FDA registration of Omacor and Lovaza for the HTG indication and treatment as an adjunct to diet for patients with “very
high” levels of triglycerides in the USA
-
2006: PB Holding acquired controlling interest in Pronova Biocare and the group was established
-
2007: Change of name to Pronova BioPharma. Listing of the company’s shares at Oslo Børs. GlaxoSmithKline acquired Pronova BioPharma’s
US distribution partner
